Shares of PureTech Health plc (OTCMKTS:PTCHF – Get Free Report) traded down 9.5% during trading on Friday . The stock traded as low as $1.99 and last traded at $1.99. 5,000 shares traded hands during trading, a decline of 84% from the average session volume of 31,001 shares. The stock had previously closed at $2.20.
PureTech Health Price Performance
The business’s 50-day moving average is $2.05 and its 200 day moving average is $2.15.
PureTech Health Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Featured Articles
- Five stocks we like better than PureTech Health
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Consumer Discretionary Stocks Explained
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What is a support level?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
